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An analysis of other primary cancers in individuals with non-Hodgkin’s lymphoma (NHL) can help to elucidate this cancer aetiology. In
all, 109451 first primary NHL were included in a pooled analysis of 13 cancer registries. The observed numbers of second cancers
were compared to the expected numbers derived from the age-, sex-, calendar period- and registry-specific incidence rates. We also
calculated the standardised incidence ratios for NHL as a second primary after other cancers. There was a 47% (95% confidence
interval 43–51%) overall increase in the risk of a primary cancer after NHL. A strongly significant (Po0.001) increase was observed
for cancers of the lip, tongue, oropharynx*, stomach, small intestine, colon*, liver, nasal cavity*, lung, soft tissues*, skin melanoma*,
nonmelanoma skin*, bladder*, kidney*, thyroid*, Hodgkin’s lymphoma*, lymphoid leukaemia* and myeloid leukaemia. Non-
Hodgkin’s lymphoma as a second primary was increased after cancers marked with an asterisk. Patterns of risk indicate a treatment
effect for lung, bladder, stomach, Hodgkin’s lymphoma and myeloid leukaemia. Common risk factors may be involved for cancers of
the lung, bladder, nasal cavity and for soft tissues, such as pesticides. Bidirectional effects for several cancer sites of potential viral origin
argue strongly for a role for immune suppression in NHL.
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The incidence of non-Hodgkin’s lymphoma (NHL) has increased
in most parts of the world (Bray et al, 2001). A comparison of
cancer registry information between 1982 and 1997 (Parkin et al,
1992, 2002) indicates that this increase is occurring at an average
annual rate of 4–5% each year, implying a doubling of NHL
incidence every 20 years. This upward trend has been observed in
all geographical regions covered by cancer registration, and is not
restricted to any particular age group or sex, or to predominantly
rural or urban areas. The reason for the increase has attracted
much speculation although there is no clear explanation for it.
It has long been recognised that clusters of second primary
cancers provide a unique clue to the understanding of cancer
aetiology and mechanisms (Hanlon, 1931). If detection and other
biases can be excluded, then the increased risk of an individual
developing more than one primary cancer may be attributed to
either (i) common risk factors between the cancers including
environmental exposures and genetic factors, or (ii) effects of
treatment, particularly chemo- and radiotherapy for the first
primaries (Boice et al, 1985). It is often possible to distinguish
between these two explanations. Cancers that share a common
aetiology are likely to be increased after each other, whereas an
increased incidence of treatment-related second primary cancers is
often unidirectional. Furthermore, an increase in treatment-related
cancers usually only becomes apparent years after the first primary
cancer. To help elucidate the potential causes of NHL and the
recent increasing incidence, we have therefore studied the
occurrence of second primary cancers in over 109000 patients
with NHL from 13 cancer registries.
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yMATERIALS AND METHODS
In order to conduct a systematic analysis of second primary
cancers, an international multicentre study has been initiated
incorporating large cancer registries which have been in operation
for at least 25 years. In all, 19 cancer registries that have
consistently reported their cancer incidence figures in Cancer
Incidence in Five Continents (Parkin et al, 2002) were invited to
participate. A similar analysis is underway in the US SEER cancer
registries and they are therefore not included in this analysis.
Consistent publication in consecutive versions in Cancer in Five
Continents was taken as a proxy measure of quality of the cancer
registry, including high levels of morphological verification and
low levels of cancers identified only through death certificates.
Of an initial group of 19 contacted registries, 15 confirmed that the
project was feasible and provided all necessary data. Two registries
were subsequently excluded because of discrepancies in the
observed rates of second primaries, leaving 13 registries in the
current analysis. These registries are British Columbia, Manitoba
and Saskatchewan (Canada), New South Wales (Australia),
Singapore, Norway, Denmark, Sweden, Finland, Iceland, Scotland,
Slovenia and Zaragoza (Spain). Some individual analyses with
partial overlap with the current data set have previously been
reported (Storm and Prener, 1985; Adami et al, 1995; Brennan
et al, 2000; Dong and Hemminki, 2001; McKenna et al, 2003).
Anonymised data were provided from each cancer registry on all
initial primary cancers, including age and sex of the subject,
diagnosis and date of the first primary, follow-up for mortality and
date and diagnosis of the second primary, if any. Information was
also obtained from each cancer registry on the set of rules used
for defining a second primary cancer. As these differ between
cancer registries, and also over time, the International Association
of Cancer Registries (IACR)/International Agency for Research on
Cancer (IARC) rules on second primary cancers were adopted as
a common set of rules (Muir and Percy, 1991). This was possible as
all participating cancer registries currently use the IACR/IARC
rules, or a local set of more extensive or detailed rules.
All cases of first primary NHL were followed up for second
primary cancer from the date of NHL diagnosis (1943–2000), to
the date of second primary cancer (1943–2000), date of death,
date of migration or end of follow-up (1992–2000). To assess any
possible excess of second primary neoplasms after NHL, we
compared the observed number of neoplasms to the expected
number derived from the age-, sex- and calendar period-specific
cancer incidence rates of first primary cancers in each of the
cancer registries. Standardised incidence ratios (SIRs) adjusted
for age, year, sex and registry were calculated using indirect
standardisation methods. Exact confidence intervals (CI) around
the SIR were calculated assuming a Poisson distribution for the
observed number of neoplasms. For those cancer sites that were
significantly increased after NHL (Po0.001), detailed SIRs were
calculated after stratifying for age, follow-up period and calendar
period. Finally, we have calculated the SIRs for NHL as a second
primary after other cancer sites as a first primary.
RESULTS
The population included 109451 NHL first primary cases and 7427
NHL cases as a second primary cancer (Table 1). Among the first
primary NHL cases, 37% provided less than 1 year of follow-up,
whereas 13% provided at least 10 years of follow-up. Among the 13
registries, 19% of the first primary NHL cases came from Sweden,
with substantial contributions also from Denmark (15%), New
South Wales (14%), Norway (13%), Scotland (10%), Finland (10%)
and British Columbia (9%).
Among the 109451 NHL first primary cases, there was a 47%
overall increase in the risk of a second primary cancer (SIR¼1.47,
95% CI 1.43–1.51) (Table 2). This relative risk was higher with
increasing time of follow-up, being 1.37 (95% CI 1.32–1.43) in the
1–4-year follow-up period, and 1.67 (95% CI 1.59–1.76) after 10
years or more (test for trend Po0.05).
A strongly significant (Po0.001) increase was observed for 18
separate cancers: lip, tongue, oropharynx, stomach, small intestine,
colon, liver, nose and nasal cavity, lung, soft tissue, skin mela-
noma and nonmelanoma skin cancer, bladder, kidney, thyroid,
Hodgkin’s lymphoma, lymphoid leukaemia and myeloid leukae-
mia. Among the 960 nonmelanoma skin cancers that occurred
after the first NHL, 36.9% were basal cell cancers and 1.5% were
Kaposi’s sarcomas. Further attention is restricted to these 18
cancer sites.
When second cancer risk was stratified by gender, there was
some evidence of a higher risk among men than women
(SIR¼1.50 vs 1.43, P for heterogeneity¼0.06), which was mainly
due to skin melanoma (SIR¼2.20 vs 1.52, Po0.01), skin
nonmelanoma (SIR¼3.77 vs 2.61, Po0.01) and multiple myeloma
(SIR¼1.30 vs 0.69, P¼0.02). Conversely, women had a higher risk
of lip (SIR¼4.07 vs 1.58, Po0.01), stomach (SIR¼1.65 vs 1.17,
Po0.01), colon (SIR¼1.47 vs 1.13, Po0.01) and lung cancers
(SIR¼1.72 vs 1.39, Po0.01).
We investigated whether any excess risk was constant over time
or whether it increased with follow-up, the latter being more
typical of a treatment effect. After excluding the first 12 months of
follow-up, a significant (Po0.05) increasing trend was observed
for only stomach, lung, bladder cancer and Hodgkin’s lymphoma,
though for all four sites an increase in risk was also seen in the
initial 1–4-year period, indicating that either the trend was not
solely a treatment effect, or alternatively that latent period for the
treatment effect could be as little as 4 years. An increased risk was
also observed with myeloid leukaemia, which was most prominent
between 5 and 9 years after NHL onset.
Six of the cancer sites showed a decreasing risk with increasing
age of NHL onset, these being stomach, lung, bladder, Hodgkin’s
lymphoma, lymphoid leukaemia and myeloid leukaemia (Table 3).
None of the cancer sites showed an increasing risk with increasing
age of onset of NHL. Regarding year of onset, few of the cancer
sites showed any increasing or decreasing trends with risk
(Table 4); the exceptions were lip and kidney, both of which
showed moderately higher relative risks after NHL diagnosed in
the later follow-up periods.
Finally, the risk of NHL after all other cancer sites was also
assessed (Table 5). Restricting attention to the 18 cancers that were
increased after NHL, 11 of these also showed increases, including
oropharynx, colon, nose and nasal cavity, soft tissue sarcoma, skin
melanoma and nonmelanoma skin cancer, bladder, kidney,
thyroid, Hodgkin’s lymphoma and lymphoid leukaemia.
DISCUSSION
Our results show a 47% (95% CI 43–51%) overall increase in the
risk of primary cancer after NHL. The different patterns of risk for
the 18 cancers with an overall increased incidence are summarised
in Table 6. This analysis of second primary cancers after NHL
suffers from several limitations. Non-Hodgkin’s lymphoma is
really a cluster of separate cancers and the lack of information on
subtypes of NHL removes the possibility of identifying more
specific relationships. We could not attempt any extensive analysis
by subtype due to the differing amount of subtype information
in individual registries, as well as the likely differing quality of
subtype information both between registries and over time. We
also have not included in this analysis any information on
treatment, because of the very limited and heterogeneous amount
of information available in all of the cancer registries. Particular
care was taken to standardise cancer site definitions between
registries and over time, although some heterogeneity among
results in the 13 registries may have occurred due to differences in
treatment and exposure, as well as specific cancer registry
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ycharacteristics. The latter source of heterogeneity was minimised
by ensuring a common protocol across the registries for reporting
second primaries, detailed comparison of results to identify
discrepancies and the dropping of two registries due to apparent
under-reporting in one and over-reporting in the other that could
not be easily explained.
Treatment effects
Five of the cancer sites (lung, bladder, stomach, Hodgkin’s
lymphoma and myeloid leukaemia) showed patterns of risk
consistent with a treatment effect, including an increase in risk
with time since NHL diagnosis and a greater risk with young age
of onset, when treatments are likely to be more intensive.
Treatment regimes for NHL typically involve chemotherapy for
middle- and high-grade subtypes, and localised radiotherapy or no
active treatment for low-grade subtypes (Travis et al, 1991). The
increase in stomach cancer risk was mainly observed at least 10
years after initial NHL diagnosis and may be due to initial
radiotherapy treatment, as gamma radiation has been shown to
increase the risk of stomach cancer (IARC Monographs Vol 75,
2000). The increasing risk of lung cancer after NHL may be also
due to radiotherapy, although radiogenic lung tumours typically
require a long latent period and the effect here was observed in the
first 4 years after NHL diagnosis. This suggests that a common risk
factor may also be present. The increasing risk of bladder cancer
after NHL is likely to be explained by treatment with cyclopho-
sphamide (IARC Monographs Suppl 7, 1987). Of interest was a
small but significant increase in risk of NHL after bladder cancer,
which could also indicate some joint exposures for the two cancers.
Although smoking is an attractive putative common risk factor
between NHL, bladder and lung cancer, the evidence for a role of
smoking in NHL has been very limited until now, with only few
studies suggesting that smoking may be associated with follicular
NHL (Herrinton and Friedman, 1998; Parker et al, 2000; Morton
et al, 2003; Stagnaro et al, 2004).
The excess of Hodgkin’s lymphoma after NHL increased with
time and was more apparent among NHL cases with a younger age
at onset. When the reverse relationship was studied, a strong but
relatively constant risk of NHL was observed after Hodgkin’s
lymphoma. The strong increase in the immediate post-diagnostic
period, and the inverse relationship of NHL after Hodgkin’s
lymphoma would argue strongly for common exposures. While the
aetiology of Hodgkin’s lymphoma is not totally clear, altered
immune function and specifically late exposure to common viruses
and Epstein–Barr virus (EBV) are thought to play a role, and may
also be involved in NHL. It should also be noted that, given the
complexities of lymphoma diagnosis, some level of misclassifica-
tion between Hodgkin’s lymphoma and NHL is inevitable (Travis
et al, 1992). Regarding myeloid leukaemia, the increase was mainly
restricted to the 5–9-year period after NHL diagnosis, and was
strongly related to young age at NHL onset. Previous studies have
Table 1 Distribution of NHL patients as first and second cancer by sex, age, follow-up, and calendar period
No. of first primary NHL (%) No. of second primary NHL
a (%)
Sex
Women 49808 (45.5) 3592 (48.4)
Men 59643 (54.5) 3835 (51.2)
Age at NHL diagnosis
Less than 56 years old 34881 (31.9) 761 (10.2)
56–65 years old 23514 (21.5) 1221 (16.4)
66–74 years old 26368 (24.1) 2133 (28.7)
At least 75 years old 24688 (22.6) 3312 (44.6)
Calendar period at NHL as a first cancer
Before 1975 17976 (16.4) 445 (6.0)
1975–1983 24553 (22.4) 1133 (15.3)
1984–1990 28828 (26.3) 2141 (28.8)
1991 or after 38094 (34.8) 3708 (49.9)
Follow-up duration
Less than 1 year 40219 (36.7) 1192 (16.0)
1–4 years 37273 (34.1) 2445 (32.9)
5–9 years 17786 (16.3) 1745 (23.5)
At least 10 years 14173 (12.9) 2045 (27.5)
Registry (follow-up period)
Australia, New South Wales (1972–1997) 15913 (14.5) 877 (11.8)
Canada, British Colombia (1970–1998) 9474 (8.7) 628 (8.5)
Canada, Manitoba (1970–1998) 3681 (3.4) 425 (5.7)
Canada, Saskatchewan (1967–1998) 2301 (2.1) 205 (2.8)
Denmark (1943–1997) 16316 (14.9) 1282 (17.3)
Finland (1953–1998) 10610 (9.7) 574 (7.7)
Iceland (1955–2000) 551 (0.5) 43 (0.6)
Norway (1953–1999) 14320 (13.1) 950 (12.8)
Singapore, Chinese (1968–1992) 1822 (1.7) 33 (0.4)
Slovenia (1961–1998) 1603 (1.5) 73 (1.0)
Spain, Zaragoza (1978–1998) 1322 (1.2) 46 (0.6)
Sweden (1961–1998) 20865 (19.1) 1608 (21.7)
UK, Scotland (1975–1996) 10673 (9.8) 683 (9.2)
Total 109451 7427
NHL, non-Hodgkin’s lymphoma.
aExcluding those following a NHL.
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specific chemotherapy regimes including the multi-drug protocol
MOPP (nitrogen mustard, vincristine, procarbazine and predni-
sone).
Ultraviolet (UV) light or altered immunity
The relationship with skin cancer was bi-directional, and similar
for both melanoma and nonmelanoma, which argues strongly
against detection bias as an explanation for the increase. Instead,
the joint association is likely to be due to a common risk factor
or shared mechanism that is stronger during the initial period of
diagnosis. The role of UV light has previously been put forward as
explaining this joint association (Cartwright et al, 1994; McMichael
and Giles, 1996). However, recent evidence fails to support such an
association (Hughes et al, 2004; Smedby et al, 2005). The joint
association with skin cancer may be due instead to a common
mechanism such as general immune suppression, possibly
modulated by UV exposure in the case of skin cancers, but by
other exposures for NHL. It is of interest that skin cancers are
strongly increased among subjects who experience extreme
immune suppression, indicating an infectious aetiology for some
of these cancers (Hemminki et al, 2003). Human papillomavirus
(HPV) types 5/8 have also been identified in nonmelanoma skin
cancers among transplant recipients (IARC Monographs Vol 64,
1995).
The increase in cancer of the oropharynx after NHL was
relatively constant over time, and was mirrored by a similar
increase in NHL after an initial diagnosis of oropharynx cancer.
The excess risk may be linked to the viral aetiology of
Table 2 Standardised incidence ratios of second primary cancers following NHL by follow-up period
Less than 1 year 1–4 years 5–9 years At least 10 years Overall
Cancer sites (ICD 9th revision) Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI P for trend
a Obs. SIR 95% CI
All malignant (140–208) 1123 1.36 1.28–1.44 2440 1.37 1.32–1.43 1646 1.55 1.48–1.63 1464 1.67 1.59–1.76 o0.01 6673 1.47 1.43–1.51
Lip (140) 10 1.59 0.76–2.92 22 1.70 1.06–2.57 23 3.17 2.01–4.75 8 1.42 0.61–2.80 0.86 63 1.96 1.51–2.51
Tongue (141) 7 2.38 0.96–4.90 20 3.12 1.91–4.82 6 1.61 0.59–3.50 10 3.41 1.64–6.28 0.93 43 2.69 1.94–3.62
Salivary gland (142) 3 1.77 0.37–5.18 9 2.47 1.13–4.68 4 1.87 0.51–4.79 3 1.70 0.35–4.98 0.54 19 2.06 1.24–3.21
Mouth (143–145) 4 0.94 0.26–2.41 17 1.83 1.07–2.93 7 1.28 0.51–2.63 6 1.36 0.50–2.96 0.45 34 1.45 1.00–2.03
Oropharynx (146) 6 3.12 1.14–6.79 8 1.86 0.80–3.67 6 2.35 0.86–5.11 4 1.97 0.54–5.03 0.86 24 2.22 1.42–3.30
Nasopharynx (147) 0 0.00 0.00–3.26 5 2.09 0.68–4.87 0 0.00 0.00–2.78 5 5.08 1.65–11.8 0.23 10 1.71 0.82–3.15
Hypopharynx (148) 0 0.00 0.00–2.24 5 1.41 0.46–3.29 1 0.49 0.01–2.72 4 2.54 0.69–6.52 0.49 10 1.13 0.54–2.09
Pharynx unspecified (149) 0 0.00 0.00–10.6 1 1.34 0.03–7.45 0 0.00 0.00–8.06 2 6.69 0.81–24.2 0.16 3 1.62 0.33–4.73
Oesophagus (150) 9 0.80 0.37–1.52 33 1.42 0.98–2.00 20 1.47 0.90–2.27 21 1.98 1.23–3.03 0.27 83 1.41 1.13–1.75
Stomach (151) 52 1.21 0.90–1.58 107 1.27 1.04–1.53 54 1.13 0.85–1.48 72 1.91 1.49–2.41 0.02 285 1.34 1.19–1.50
Small intestine (152) 8 3.36 1.45–6.62 15 2.90 1.62–4.79 5 1.62 0.53–3.78 5 1.90 0.62–4.43 0.30 33 2.49 1.71–3.49
Colon (153) 67 0.97 0.75–1.23 189 1.26 1.09–1.46 126 1.39 1.16–1.66 114 1.51 1.25–1.82 0.12 496 1.29 1.18–1.41
Rectum (154) 31 0.74 0.50–1.05 99 1.10 0.89–1.34 53 0.99 0.74–1.29 69 1.55 1.20–1.96 0.05 252 1.09 0.96–1.24
Liver (155) ( 1552) 17 2.15 1.25–3.44 21 1.24 0.77–1.90 13 1.29 0.69–2.21 16 1.89 1.08–3.07 0.23 67 1.55 1.20–1.96
Gall bladder, bile ducts (156) 12 1.34 0.69–2.34 16 0.85 0.48–1.38 17 1.50 0.87–2.40 15 1.57 0.88–2.58 0.07 60 1.23 0.94–1.58
Pancreas (157) 23 0.89 0.56–1.33 51 0.93 0.69–1.22 36 1.11 0.78–1.54 40 1.47 1.05–2.00 0.03 150 1.07 0.91–1.25
Peritoneum (158) 3 3.07 0.63–8.98 2 0.96 0.12–3.48 1 0.81 0.02–4.49 0 0.00 0.00–3.58 0.36 6 1.13 0.41–2.45
Nose and nasal cavity (160) 5 3.27 1.06–7.64 8 2.47 1.07–4.86 4 2.12 0.58–5.42 3 1.90 0.39–5.55 0.68 20 2.43 1.48–3.75
Larynx (161) 3 0.39 0.08–1.14 18 1.09 0.65–1.73 13 1.38 0.73–2.36 15 2.10 1.17–3.46 0.07 49 1.20 0.89–1.59
Lung (162) 137 1.26 1.06–1.49 300 1.30 1.16–1.46 230 1.72 1.50–1.96 187 1.78 1.53–2.05 o0.01 854 1.48 1.38–1.58
Bone (170) 2 1.99 0.24–7.17 5 2.39 0.78–5.58 3 2.50 0.52–7.31 4 4.21 1.15–10.8 0.42 14 2.67 1.46–4.48
Soft tissue sarcoma (171) 7 1.92 0.77–3.95 14 1.77 0.97–2.97 15 3.20 1.79–5.28 13 3.40 1.81–5.82 0.07 49 2.44 1.81–3.23
Melanoma of skin (172) 48 2.09 1.54–2.77 113 2.15 1.77–2.58 60 1.86 1.42–2.40 37 1.38 0.97–1.90 0.02 258 1.92 1.69–2.16
Other neoplasm of skin (173) 120 2.27 1.88–2.71 402 3.56 3.22–3.92 274 3.99 3.53–4.49 164 2.82 2.41–3.29 0.05 960 3.28 3.07–3.49
Female breast (174) 61 0.81 0.62–1.04 168 0.97 0.83–1.13 102 0.96 0.78–1.17 99 1.14 0.92–1.38 0.27 430 0.97 0.88–1.07
Male breast (175) 2 2.55 0.31–9.22 2 1.20 0.14–4.33 1 1.01 0.03–5.64 2 2.52 0.31–9.11 0.48 7 1.65 0.66–3.41
Cervix uteri (180) 8 0.91 0.39–1.79 21 1.10 0.68–1.69 12 1.08 0.56–1.89 10 1.14 0.55–2.10 0.94 51 1.07 0.80–1.41
Placenta (181) 0 0.00 0.00–311 0 0.00 0.00–136 0 0.00 0.00–224 0 0.00 0.00–292 NA 0 0.00 0.00–54.2
Corpus uteri (182) 12 0.72 0.37–1.26 33 0.87 0.60–1.23 22 0.96 0.60–1.45 14 0.73 0.40–1.22 0.66 81 0.84 0.67–1.04
Ovary (183) 14 0.96 0.53–1.61 28 0.86 0.57–1.24 22 1.11 0.70–1.69 23 1.40 0.89–2.11 0.07 87 1.04 0.84–1.29
Other female genital (179,184) 4 1.02 0.28–2.60 6 0.70 0.26–1.52 11 2.10 1.05–3.76 7 1.58 0.64–3.27 0.10 28 1.26 0.84–1.83
Prostate (185) 134 1.14 0.96–1.36 243 0.96 0.84–1.09 161 1.05 0.89–1.22 169 1.29 1.10–1.50 o0.01 707 1.08 1.00–1.16
Testis (186) 7 4.25 1.71–8.75 4 1.09 0.30–2.78 5 2.25 0.73–5.25 3 1.40 0.29–4.08 0.66 19 1.96 1.18–3.06
Other male genital (187) 0 0.00 0.00–2.64 5 1.70 0.55–3.98 4 2.36 0.64–6.05 4 2.77 0.75–7.09 0.46 13 1.74 0.93–2.98
Bladder (188,189.3,189.4) 52 1.24 0.93–1.63 108 1.21 0.99–1.46 85 1.61 1.28–1.98 98 2.21 1.80–2.70 o0.01 343 1.50 1.35–1.67
Kidney (189) ( 189.3, 189.4) 114 5.13 4.23–6.16 52 1.08 0.80–1.41 44 1.54 1.12–2.07 29 1.21 0.81–1.74 0.43 239 1.94 1.70–2.21
Eye (190) 1 0.52 0.01–2.92 9 2.19 1.00–4.16 6 2.50 0.92–5.44 2 1.01 0.12–3.63 0.41 18 1.73 1.03–2.73
Brain, nervous system (191–192) 13 1.29 0.69–2.21 23 1.02 0.65–1.54 23 1.75 1.11–2.62 17 1.59 0.93–2.55 0.12 76 1.35 1.06–1.69
Thyroid gland (193) 13 2.95 1.57–5.05 16 1.64 0.94–2.66 12 2.07 1.07–3.61 15 3.13 1.75–5.16 0.07 56 2.26 1.71–2.94
Other endocrine gland (194, 164.0) 4 5.68 1.55–14.5 3 1.97 0.41–5.77 1 1.12 0.03–6.22 0 0.00 0.00–5.12 0.22 8 2.08 0.90–4.10
Hodgkin’s disease (201) 10 3.93 1.88–7.23 19 3.54 2.13–5.53 21 6.87 4.25–10.5 19 7.69 4.63–12.0 0.01 69 5.14 4.00–6.50
Multiple myeloma (203) 15 1.28 0.72–2.11 22 0.87 0.54–1.31 15 0.99 0.55–1.63 16 1.25 0.72–2.03 0.27 68 1.05 0.81–1.33
Lymphoid leukaemia (204) 18 1.99 1.18–3.15 52 2.71 2.02–3.55 36 3.11 2.18–4.30 25 2.59 1.68–3.83 0.98 131 2.65 2.21–3.14
Myeloid leukaemia (205) 9 1.45 0.66–2.75 21 1.60 0.99–2.44 15 1.93 1.08–3.18 6 0.94 0.34–2.04 0.38 51 1.52 1.13–2.00
Other leukaemia (206–208) 16 3.54 2.02–5.75 32 3.27 2.24–4.61 19 3.28 1.99–5.12 16 3.24 1.85–5.26 0.98 83 3.31 2.64–4.11
Other malignant than defined 42 1.09 0.79–1.48 93 1.12 0.90–1.37 58 1.15 0.87–1.48 73 1.75 1.37–2.20 0.01 266 1.24 1.10–1.40
NHL, non-Hodgkin’s lymphoma.
aExcluding the category ‘Less than 1 year’. NA, not applicable.
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yoropharyngeal cancer via moderate immune suppression. A
substantial proportion of oropharyngeal cancers are thought to
be related to HPV infection, in particular HPV 16 (IARC
Monographs Vol 64, 1995). Similarly, the excess of liver cancer
may be related to mild immunosuppression or even more directly
by infection with hepatitis C, which has been recently shown to
be involved with NHL (Negri et al, 2004). If immune suppression
is the common mechanism involved in the excess risk of skin,
oropharyngeal and hepatic cancers, then chemotherapy might be
partly responsible for that, as many forms of chemotherapy are
also immunosuppressive.
Other common risk factors
Other cancer sites with strong bi-directional effects included nasal
cavity cancer, soft tissue sarcoma and thyroid cancer. Regarding
soft tissue sarcoma, its aetiology is little understood although an
increase in risk has been reported among workers exposed to
phenoxy acid herbicides (Kogevinas et al, 1997), which has also
been linked with NHL. The epidemiology of thyroid cancer is
poorly understood, with ionising radiation, particularly at a young
age, being the one consistently observed risk factor. However, it is
unlikely that ionising radiation could explain the joint association
between these cancers given that it does not appear to increase
the risk of NHL. It is however possible that both cancers may
share a common genetic pathway given the well-known increased
risk of NHL among ataxia-telangiectasia (AT) homozygotes, and a
possible increased risk of thyroid cancer among relatives of AT
patients (Geoffroy-Perez et al, 2001), although this observation was
based on one case only. Investigation of DNA repair genes in NHL,
in particular double-strand break repair, would therefore appear to
be of interest.
Table 3 Standardised incidence ratios of selected second primary cancers after NHL by age at NHL
Less than 56 years old 56–65 years old 66–74 years old At least 75 years old
Cancer sites (ICD 9th rev.) Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI P for trend
Lip (140) 8 1.28 0.55–2.51 18 2.01 1.19–3.18 26 2.52 1.64–3.70 11 1.66 0.83–2.97 0.45
Tongue (141) 16 3.67 2.10–5.96 14 2.93 1.60–4.92 8 1.80 0.78–3.55 5 2.06 0.67–4.80 0.10
Oropharynx (146) 7 1.91 0.77–3.94 7 2.00 0.80–4.13 8 3.09 1.33–6.08 2 1.88 0.23–6.80 0.58
Stomach (151) 59 1.97 1.50–2.54 81 1.53 1.21–1.90 85 1.15 0.92–1.42 60 1.07 0.82–1.38 o0.01
Small intestine (152) 10 3.57 1.71–6.56 8 2.17 0.94–4.28 10 2.38 1.14–4.38 5 1.94 0.63–4.52 0.29
Colon (153) 90 1.56 1.25–1.91 125 1.27 1.05–1.51 159 1.20 1.02–1.40 122 1.27 1.06–1.52 0.18
Liver (155) ( 155.2) 16 2.21 1.26–3.59 15 1.27 0.71–2.09 21 1.41 0.87–2.16 15 1.60 0.89–2.64 0.48
Nose and nasal cavity (160) 6 3.30 1.21–7.18 6 2.56 0.94–5.58 4 1.57 0.43–4.02 4 2.61 0.71–6.68 0.49
Lung (162) 231 2.18 1.91–2.48 288 1.59 1.41–1.78 246 1.24 1.09–1.41 89 0.95 0.76–1.17 o0.01
Soft tissue sarcoma (171) 16 3.10 1.77–5.03 11 2.11 1.05–3.77 12 2.04 1.05–3.56 10 2.62 1.26–4.83 0.56
Melanoma of skin (172) 67 1.53 1.18–1.94 83 2.25 1.79–2.79 67 1.92 1.49–2.44 41 2.17 1.55–2.94 0.11
Other neoplasm of skin (173) 157 3.05 2.59–3.57 243 3.42 3.00–3.88 327 3.47 3.10–3.87 233 3.06 2.68–3.48 0.93
Bladder (188, 189.3, 189.4) 84 2.34 1.87–2.90 85 1.37 1.10–1.70 102 1.29 1.05–1.56 72 1.40 1.09–1.76 o0.01
Kidney (189) ( 189.3, 189.4) 55 2.10 1.58–2.73 67 1.86 1.44–2.36 78 1.98 1.57–2.48 39 1.82 1.29–2.48 0.62
Thyroid gland (193) 22 2.45 1.54–3.71 12 1.94 1.00–3.38 10 1.65 0.79–3.04 12 3.39 1.75–5.92 0.75
Hodgkin’s disease (201) 41 7.87 5.65–10.7 13 3.89 2.07–6.66 11 3.46 1.73–6.18 4 2.34 0.64–6.00 o0.01
Lymphoid leukaemia (204) 45 5.44 3.97–7.28 51 3.91 2.91–5.15 21 1.28 0.79–1.95 14 1.19 0.65–2.00 o0.01
Myeloid leukaemia (205) 17 2.52 1.47–4.04 15 1.78 1.00–2.93 12 1.09 0.57–1.91 7 0.94 0.38–1.94 o0.01
NHL, non-Hodgkin’s lymphoma.
Table 4 Standardised incidence ratios of selected cancer sites after NHL by calendar period at NHL
Before 1975 1975–1983 1984–1990 1991 or after
Cancer sites (ICD 9th rev.) Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI P for trend
Lip (140) 7 0.91 0.37–1.88 17 1.65 0.96–2.65 25 2.82 1.82–4.17 14 2.62 1.43–4.40 o 0.01
Tongue (141) 9 3.49 1.60–6.63 12 2.42 1.25–4.22 18 3.58 2.12–5.66 4 1.16 0.32–2.98 0.22
Oropharynx (146) 3 1.91 0.39–5.59 7 2.12 0.85–4.38 6 1.70 0.62–3.70 8 3.30 1.43–6.51 0.42
Stomach (151) 93 1.53 1.24–1.88 82 1.25 0.99–1.55 70 1.28 0.99–1.61 40 1.27 0.91–1.73 0.26
Small intestine (152) 6 2.41 0.88–5.25 13 3.36 1.79–5.75 10 2.49 1.19–4.58 4 1.38 0.38–3.53 0.29
Colon (153) 79 1.19 0.94–1.48 163 1.37 1.16–1.59 143 1.20 1.02–1.42 111 1.38 1.14–1.66 0.61
Liver (155) ( 155.2) 13 1.69 0.90–2.89 23 1.80 1.14–2.70 21 1.55 0.96–2.36 10 1.07 0.52–1.98 0.23
Nose and nasal cavity (160) 6 3.28 1.20–7.13 6 2.44 0.90–5.31 7 2.91 1.17–6.00 1 0.65 0.02–3.60 0.20
Lung (162) 131 1.40 1.17–1.66 296 1.56 1.39–1.75 277 1.53 1.36–1.72 150 1.32 1.11–1.54 0.51
Soft tissue sarcoma (171) 4 1.03 0.28–2.65 15 2.49 1.40–4.11 17 2.84 1.65–4.55 13 3.09 1.64–5.28 0.06
Melanoma of skin (172) 41 2.48 1.78–3.37 66 1.69 1.31–2.15 90 1.97 1.59–2.42 61 1.82 1.39–2.33 0.39
Other neoplasm of skin (173) 150 3.31 2.80–3.88 261 3.14 2.77–3.54 331 3.47 3.10–3.86 218 3.17 2.76–3.62 0.95
Bladder (188,189.3,189.4) 74 1.84 1.45–2.31 104 1.49 1.22–1.81 96 1.36 1.10–1.66 69 1.43 1.11–1.81 0.11
Kidney (189) ( 189.3,189.4) 39 1.70 1.21–2.33 63 1.73 1.33–2.22 61 1.61 1.23–2.07 76 2.94 2.32–3.68 o 0.01
Thyroid gland (193) 13 2.57 1.37–4.40 18 2.48 1.47–3.92 15 2.06 1.15–3.39 10 1.94 0.93–3.57 0.41
Hodgkin’s disease (201) 24 6.73 4.31–10.0 22 5.28 3.31–8.00 11 3.10 1.55–5.54 12 5.56 2.87–9.72 0.20
Lymphoid leukaemia (204) 27 2.85 1.88–4.14 45 2.92 2.13–3.91 39 2.61 1.86–3.57 20 2.07 1.26–3.20 0.24
Myeloid leukaemia (205) 3 0.50 0.10–1.46 20 1.82 1.11–2.81 15 1.47 0.83–2.43 13 2.03 1.08–3.48 0.09
NHL, non-Hodgkin’s lymphoma.
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Given the bi-directional association between NHL and kidney
cancer, common exposures for the two cancers may be suspected.
However, the increase in kidney cancer after NHL was strongly
concentrated on the first 12 months after diagnosis, indicating a
possible detection bias. A similar increased risk of kidney cancer
after NHL that was largely restricted to the initial follow-up period
was also observed among 29153 SEER NHL patients that was
thought to be probably explained by detection bias (Travis et al,
1991). The excess risk of small intestine cancer after NHL was also
concentrated in the first 12 months after NHL diagnosis, again
arguing for detection bias. Similarly, the increase in lymphoid
leukaemia after NHL is likely to be partially explained by
misclassification between these two sites as well as some cases of
NHL developing into lymphoid leukaemias.
Extra-nodal lymphomas may also be classified according to the
primary site resulting in spurious associations. It has been
estimated that up to 33% of NHL are extra-nodal, with the most
common sites being stomach, skin, small intestine and oropharynx
(Newton et al, 1997). Primary cancers at all of these sites were
increased after NHL in the current analysis. Given that nodal and
extra-nodal NHL have been classified separately only with more
recent classification schemes, we have been able to ascertain
nodular status for 24018 of the 109451 NHL patients (registries
that utilised ICDO-1 or ICDO-2 codes, wholly or partly included
British Columbia, Saskatchewan, Scotland, Spain and New South
Wales): 18812 were nodular, 1782 originated from other lymphatic
tissues (such as tonsils, spleen, thymus and Waldeyer’s ring) and
3424 were extra-lymphatic. The overall increased risk of a second
primary cancer was 1.34 (95% CI 1.26–1.42) after nodular NHL,
1.45 (95% CI 1.21–1.72) after other lymphatic tissue NHL and 1.37
Table 5 Standardised incidence ratios of NHL after other first primary cancers by follow-up period
Less than 1 year 1–4 years 5–9 years At least 10 years Overall
Cancer sites (ICD 9th revision) Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI Obs. SIR 95% CI P for trend
a Obs. SIR 95% CI
Lip (140) 8 0.88 0.38–1.74 43 1.40 1.01–1.88 31 1.11 0.75–1.58 44 1.06 0.77–1.43 0.21 126 1.16 0.96–1.38
Tongue (141) 7 2.11 0.85–4.34 5 0.74 0.24–1.72 10 2.13 1.02–3.91 6 1.25 0.46–2.72 0.35 28 1.43 0.95–2.06
Salivary gland (142) 3 1.41 0.29–4.13 10 1.74 0.83–3.20 9 1.87 0.85–3.55 13 1.43 0.76–2.45 0.62 35 1.61 1.12–2.24
Mouth (143–145) 16 3.15 1.80–5.11 20 1.76 1.08–2.72 12 1.55 0.80–2.70 14 1.86 1.02–3.12 0.92 62 1.96 1.50–2.51
Oropharynx (146) 7 3.38 1.36–6.96 14 3.58 1.95–6.01 2 0.82 0.10–2.95 6 2.81 1.03–6.12 0.38 29 2.75 1.84–3.94
Nasopharynx (147) 4 3.07 0.84–7.86 7 2.50 1.00–5.14 5 2.64 0.86–6.16 8 3.37 1.45–6.64 0.57 24 2.87 1.84–4.26
Hypopharynx (148) 0 0.00 0.00–2.23 1 0.45 0.01–2.51 1 0.90 0.02–5.01 1 1.17 0.03–6.54 0.47 3 0.51 0.11–1.50
Pharynx unspecified (149) 0 0.00 0.00–11.6 0 0.00 0.00–8.37 2 8.41 1.02–30.4 0 0.00 0.00–19.6 0.61 2 1.69 0.20–6.10
Oesophagus (150) 7 0.85 0.34–1.75 5 0.82 0.26–1.90 3 1.04 0.21–3.03 0 0.00 0.00–1.41 0.26 15 0.75 0.42–1.24
Stomach (151) 38 1.16 0.82–1.59 34 0.80 0.55–1.11 35 1.27 0.88–1.77 48 1.46 1.07–1.93 o0.01 155 1.14 0.97–1.34
Small intestine (152) 1 0.47 0.01–2.64 9 1.94 0.89–3.69 7 2.27 0.91–4.68 1 0.29 0.01–1.63 0.08 18 1.36 0.81–2.15
Colon (153) 95 1.29 1.05–1.58 180 1.07 0.92–1.24 124 1.11 0.92–1.32 135 1.25 1.05–1.48 0.19 534 1.16 1.06–1.26
Rectum (154) 40 0.84 0.60–1.14 108 1.00 0.82–1.20 60 0.87 0.66–1.12 76 1.07 0.84–1.34 0.71 284 0.96 0.85–1.08
Liver (155) ( 1552) 5 1.76 0.57–4.10 0 0.00 0.00–1.97 0 0.00 0.00–4.97 0 0.00 0.00–4.30 NA 5 0.79 0.26–1.85
Gallbladder, bile ducts (156) 3 0.61 0.13–1.77 3 0.63 0.13–1.83 2 0.80 0.10–2.90 3 1.22 0.25–3.57 0.42 11 0.75 0.37–1.34
Pancreas (157) 11 0.96 0.48–1.72 6 1.18 0.43–2.56 3 1.26 0.26–3.68 3 1.19 0.25–3.47 0.98 23 1.07 0.68–1.61
Peritoneum (158) 0 0.00 0.00–5.50 2 2.04 0.25–7.35 3 5.62 1.16–16.4 0 0.00 0.00–6.56 0.60 5 1.82 0.59–4.24
Nose and nasal cavity (160) 4 2.14 0.58–5.47 7 1.68 0.68–3.47 6 2.02 0.74–4.39 6 1.57 0.58–3.41 0.91 23 1.79 1.14–2.69
Larynx (161) 11 1.13 0.57–2.03 35 1.29 0.90–1.80 25 1.16 0.75–1.71 20 0.83 0.51–1.28 0.12 91 1.10 0.89–1.35
Lung (162) 86 1.17 0.93–1.44 73 1.08 0.85–1.36 35 1.02 0.71–1.42 37 1.20 0.84–1.65 0.70 231 1.12 0.98–1.27
Bone (170) 1 0.95 0.02–5.29 6 2.39 0.88–5.21 2 0.93 0.11–3.35 5 1.07 0.35–2.50 0.19 14 1.35 0.74–2.26
Soft tissue sarcoma (171) 14 3.43 1.88–5.76 21 2.05 1.27–3.13 12 1.48 0.76–2.58 21 1.45 0.90–2.21 0.27 68 1.84 1.43–2.33
Melanoma of skin (172) 60 2.09 1.60–2.70 137 1.58 1.32–1.87 99 1.40 1.14–1.71 99 1.08 0.88–1.32 o0.01 395 1.42 1.29–1.57
Other neoplasm of skin (173) 203 2.65 2.30–3.04 479 2.11 1.92–2.30 265 1.62 1.43–1.82 243 1.54 1.35–1.74 o0.01 1190 1.90 1.79–2.01
Female breast (174) 96 1.01 0.82–1.23 266 0.91 0.80–1.03 271 1.20 1.06–1.35 397 1.39 1.26–1.54 o0.01 1030 1.15 1.08–1.22
Male breast (175) 1 0.97 0.02–5.42 3 1.04 0.21–3.03 3 1.60 0.33–4.68 4 2.33 0.64–5.97 0.28 11 1.46 0.73–2.62
Cervix uteri (180) 14 1.31 0.72–2.20 40 1.28 0.91–1.74 50 1.52 1.13–2.01 167 1.46 1.25–1.70 0.55 271 1.43 1.27–1.61
Placenta (181) 0 0.00 0.00–237 0 0.00 0.00–60.8 0 0.00 0.00–37.3 0 0.00 0.00–6.35 NA 0 0.00 0.00–4.88
Corpus uteri (182) 25 1.23 0.79–1.81 60 0.93 0.71–1.20 74 1.19 0.93–1.49 127 1.13 0.94–1.34 0.29 286 1.10 0.98–1.24
Ovary (183) 10 0.72 0.34–1.32 14 0.50 0.28–0.84 30 1.44 0.97–2.05 62 1.55 1.19–1.99 o0.01 116 1.13 0.93–1.36
Other female genital (179,184) 9 1.97 0.90–3.75 8 0.73 0.31–1.43 11 1.25 0.62–2.23 17 1.25 0.73–2.00 0.23 45 1.18 0.86–1.58
Prostate (185) 194 1.30 1.12–1.50 359 0.98 0.88–1.08 191 1.11 0.96–1.28 78 1.02 0.81–1.28 0.37 822 1.08 1.00–1.15
Testis (186) 12 5.97 3.09–10.4 10 1.38 0.66–2.53 11 1.30 0.65–2.33 36 1.57 1.10–2.17 0.63 69 1.70 1.32–2.15
Other male genital (187) 4 2.13 0.58–5.47 11 2.15 1.08–3.86 4 0.98 0.27–2.51 7 1.29 0.52–2.66 0.26 26 1.58 1.03–2.31
Bladder (188,189.3,189.4) 59 1.15 0.87–1.48 159 1.17 1.00–1.37 103 1.05 0.86–1.28 113 1.22 1.01–1.47 0.84 434 1.15 1.04–1.26
Kidney (189) ( 189.3,189.4) 31 1.51 1.02–2.14 57 1.21 0.91–1.56 39 1.19 0.85–1.63 41 1.22 0.88–1.66 0.96 168 1.25 1.07–1.46
Eye (190) 4 1.56 0.43–4.01 12 1.56 0.80–2.72 5 0.83 0.27–1.94 14 1.49 0.81–2.49 0.95 35 1.36 0.95–1.89
Brain, nervous system (191–192) 7 1.09 0.44–2.25 15 1.99 1.11–3.28 14 2.35 1.28–3.94 14 1.11 0.60–1.86 0.10 50 1.53 1.14–2.02
Thyroid gland (193) 22 4.78 3.00–7.24 20 1.37 0.84–2.12 19 1.34 0.81–2.09 41 1.51 1.08–2.04 0.70 102 1.68 1.37–2.04
Other endocrine gland (194, 164.0) 3 5.61 1.16–16.4 6 4.53 1.66–9.86 2 1.84 0.22–6.65 2 1.34 0.16–4.83 0.10 13 2.93 1.56–5.00
Hodgkin’s disease (201) 14 5.29 2.89–8.87 39 5.64 4.01–7.71 46 7.50 5.49–10.0 70 6.29 4.90–7.94 0.70 169 6.30 5.39–7.32
Multiple myeloma (203) 13 1.09 0.58–1.86 38 1.69 1.19–2.31 20 2.51 1.53–3.87 8 1.96 0.84–3.85 0.36 79 1.70 1.34–2.11
Lymphoid leukaemia (204) 17 1.63 0.95–2.61 79 2.92 2.31–3.64 65 4.36 3.37–5.56 33 3.90 2.69–5.48 0.05 194 3.19 2.76–3.67
Myeloid leukaemia (205) 7 1.55 0.62–3.19 8 1.27 0.55–2.50 4 1.83 0.50–4.69 3 2.31 0.48–6.76 0.33 22 1.54 0.96–2.33
Other leukaemia (206–208) 8 2.71 1.17–5.35 15 3.05 1.71–5.03 6 1.87 0.68–4.06 9 2.89 1.32–5.48 0.79 38 2.68 1.89–3.67
NHL, non-Hodgkin’s lymphoma.
aExcluding the category ‘Less than 1 year’. NA, not applicable.
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y(95% CI 1.20–1.72) after extra-nodular NHL. Of the 18 sites, the 10
that increased after all NHL were still significantly increased after
nodular NHL (all except lip, stomach, small intestine, colon, liver,
nasal cavity, bladder and myeloid leukaemia). The absence of an
increased risk for these eight sites is likely to be due to the much
reduced power resulting from the smaller sample size. However, it
is of interest to note that increased risks after extra-lymphatic NHL
were observed for both colon (SIR¼1.59, 95% CI 1.02–2.37) and
stomach (SIR¼1.89, 95% CI 0.91–3.48), and the misclassification
with cancer from the corresponding organ is likely to explain the
overall increased risk of colon and stomach cancer after NHL.
In conclusion, this analysis of second primary cancers after NHL
provided evidence for a treatment-related effect for cancers of
the bladder, lung, stomach, myeloid leukaemia and Hodgkin’s
lymphoma. Nontreatment-related associations were observed for
melanoma and nonmelanoma skin cancer, for which immune
suppression as a common underlying mechanism is a strong
candidate. Exposure to pesticides deserves further attention in
individual level studies, as suggested by the bi-directional
association with soft tissue sarcomas.
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With calendar
period at NHL
diagnosis
Risk of NHL as a
second primary
cancer and trend
with time since the
first cancer
(Po0.05) Comments
Lip (140) — — s 1.16 (0.96–1.38) No trend Common exposure or mechanism
Tongue (141) — — — 1.43 (0.95–2.06) No trend Common exposure or mechanism
Oropharynx (146) — — — 2.75 (1.84–3.94) No trend Common exposure or mechanism
Stomach (151) sr — 1.14 (0.97–1.34) s Treatment effect or misclassification of
extranodal NHL
Small intestine (152) — — — 1.36 (0.81–2.15) No trend Detection bias
Colon (153) — — — 1.16 (1.06–1.26) No trend Misclassification of extranodal NHL
Liver (155) ( 155.2) — — — 0.79 (0.26–1.85) No trend Common exposure or mechanism
Nose and nasal cavity (160) — — — 1.79 (1.14–2.69) No trend Common exposure or mechanism
Lung (162) sr — 1.12 (0.98–1.27) No trend Treatment effect +common exposure
Soft tissue sarcoma (171) — — — 1.84 (1.43–2.33) No trend Common exposure or mechanism
Melanoma of skin (172) r — — 1.42 (1.29–1.57) r Common exposure or mechanism
Other neoplasm of skin (173) — — — 1.90 (1.79–2.01) r Common exposure or mechanism
Bladder (188, 189.3, 189.4) sr — 1.15 (1.04–1.26) No trend Treatment effect +common exposure
Kidney (189) ( 189.3, 189.4) — — s 1.25 (1.07–1.46) No trend Detection bias
Thyroid gland (193) — — — 1.68 (1.37–2.04) No trend Common exposure or mechanism
Hodgkin’s disease (201) sr — 6.30 (5.39–7.32) No trend Treatment, common exposure or
misclassifciation
Lymphoid leukaemia (204) — r — 3.19 (2.76–3.67) No trend Misclassification and common exposure
Myeloid leukaemia (205) — r — 1.54 (0.96–2.33) No trend Treatment effect
NHL, non-Hodgkin’s lymphoma.
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